Dynamic Regulatory Assessment: Unpacking the Process Reveals Readiness to Pilot for Europe-An EFPIA View.

Area of Science:

• Regulatory Science
• Pharmaceutical Development
• European Health Policy

Background:

• The European Economic Area's medicines regulatory network involves 30 National Competent Authorities (NCAs) and the European Medicines Agency (EMA).
• Current knowledge management between medicine developers and regulatory bodies is fragmented and inefficient due to varied involvement in medicine lifecycles.
• This inefficiency can hinder the continuous building of knowledge essential for drug development.

Purpose of the Study:

• To unpack the Dynamic Regulatory Assessment (DRA) concept, focusing on Discrete Data Packets (DDPs).
• To demonstrate how DDPs can foster efficient and predictable data release for promising medicines.
• To advocate for the immediate piloting of the DRA concept with European regulators.

Main Methods:

• Conceptual analysis and commentary building on previous work.
• Focus on the mechanics of Discrete Data Packets (DDPs) within the DRA framework.
• Exploration of how iterative data release and assessment can enhance regulatory processes.

Main Results:

• DRA, utilizing DDPs, can create increased connectedness within the regulatory network.
• Iterative release and assessment of DDPs at agreed milestones can lead to more efficient medicine development.
• The proposed approach aims to facilitate faster authorization of new medicines.

Conclusions:

• Dynamic Regulatory Assessment (DRA) presents a viable strategy to improve knowledge management and regulatory efficiency.
• Discrete Data Packets (DDPs) are central to enabling continuous knowledge building and predictable data flow.
• There is a clear case for piloting the DRA concept with European regulators to realize its potential benefits.